Zoetis (NYSE:ZTS) Earns "Hold (C-)" Rating from Weiss Ratings

Key Points

• Zoetis has received a "Hold (C-)" rating from Weiss Ratings, which has been reiterated in recent reports.
• Analysts have differing views on Zoetis, with Piper Sandler upgrading their price target to $215.00 while UBS lowered theirs to $158.00.
• The company's latest quarterly earnings showed an EPS of $1.76, exceeding expectations and indicating a 4.2% revenue growth year-over-year.

Zoetis (NYSE:ZTS - Get Free Report)'s stock had its "hold (c-)" rating reiterated by analysts at Weiss Ratings in a research note issued on Friday,Weiss Ratings reports.

Other analysts have also recently issued reports about the company. Piper Sandler upped their price objective on Zoetis from $210.00 to $215.00 and gave the stock an "overweight" rating in a report on Monday, August 11th. Leerink Partnrs cut Zoetis from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 17th. Argus reaffirmed a "buy" rating and set a $190.00 price objective on shares of Zoetis in a report on Tuesday, September 9th. UBS Group decreased their price objective on Zoetis from $165.00 to $158.00 and set a "neutral" rating on the stock in a report on Monday. Finally, Leerink Partners cut Zoetis from an "outperform" rating to a "market perform" rating and decreased their price objective for the stock from $180.00 to $155.00 in a report on Thursday, July 17th. Four investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of "Hold" and a consensus price target of $195.00.

Zoetis Price Performance

NYSE ZTS traded down $0.06 during trading hours on Friday, reaching $146.34. The company's stock had a trading volume of 481,963 shares, compared to its average volume of 3,017,962. The firm's 50-day moving average price is $148.34 and its 200-day moving average price is $153.49. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05. Zoetis has a 1 year low of $139.34 and a 1 year high of $184.40. The company has a market capitalization of $64.85 billion, a price-to-earnings ratio of 25.21, a PEG ratio of 2.36 and a beta of 0.90.

Zoetis (NYSE:ZTS - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 EPS for the quarter, topping analysts' consensus estimates of $1.62 by $0.14. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The company had revenue of $2.46 billion for the quarter, compared to analysts' expectations of $2.41 billion. During the same period in the previous year, the firm earned $1.56 EPS. The firm's revenue was up 4.2% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, equities research analysts predict that Zoetis will post 6.07 EPS for the current fiscal year.

Institutional Trading of Zoetis

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Nova Wealth Management Inc. bought a new position in Zoetis in the 1st quarter valued at $25,000. Halbert Hargrove Global Advisors LLC grew its position in Zoetis by 496.6% in the 3rd quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company's stock valued at $25,000 after acquiring an additional 144 shares during the last quarter. 1248 Management LLC bought a new position in Zoetis in the 1st quarter valued at $27,000. Saudi Central Bank bought a new position in Zoetis in the 1st quarter valued at $29,000. Finally, Cornerstone Planning Group LLC grew its position in Zoetis by 79.3% in the 1st quarter. Cornerstone Planning Group LLC now owns 199 shares of the company's stock valued at $30,000 after acquiring an additional 88 shares during the last quarter. Hedge funds and other institutional investors own 92.80% of the company's stock.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.